---
title: "CytoMed Therapeutics gets Nasdaq bid price notice"
url: "https://aibio.space/news/cytomed-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-5/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-10-13"
section: "Listings"
tickers: "NASDAQ:GDTC"
source: "https://www.sec.gov/Archives/edgar/data/1873093/000149315226046630/ex99-1.htm"
summary: "Nasdaq said the ordinary shares closed below US$1.00 for 30 consecutive business days. The letter has no current effect on the listing or trading."
---

By the aibio.space news desk.

Sources

- [CytoMed Therapeutics Limited 6-K (2026-10-13)](https://www.sec.gov/Archives/edgar/data/1873093/000149315226046630/ex99-1.htm)

[GDTC](https://aibio.space/companies/cytomed-therapeutics/)

2026-10-13

# CytoMed Therapeutics gets Nasdaq bid price notice, has until April 5, 2027

Tickers [GDTC](https://aibio.space/companies/cytomed-therapeutics/)

Nasdaq said the ordinary shares closed below US$1.00 for 30 consecutive business days. The letter has no current effect on the listing or trading.

## Key facts

- **Company**: CytoMed Therapeutics Limited (NASDAQ: GDTC)

- **News type**: Listings

- **Primary source**: [CytoMed Therapeutics Limited 6-K (2026-10-13)](https://www.sec.gov/Archives/edgar/data/1873093/000149315226046630/ex99-1.htm)

*Stone columns of a government building. Photo: The Building Envelope, CC0, via StockSnap. The picture shows the field, not the companies named.*

CytoMed Therapeutics Limited said it received a notice from the staff of the Nasdaq Listing Qualifications department on October 6, 2026. The Singapore-based company announced it on October 9, 2026.

Nasdaq said the closing bid price of the company's ordinary shares had been below the minimum of US$1.00 per share for the last 30 consecutive business days. The requirement is set out in Nasdaq Listing Rule 5550(a)(2). The letter has no current effect on the listing or trading of the shares on Nasdaq.

Under Nasdaq Listing Rule 5810(c)(3)(A), the company has a compliance period of 180 calendar days, or until April 5, 2027. If the closing bid price is US$1.00 per share or higher for at least ten consecutive business days in that period, Nasdaq will confirm compliance in writing and close the matter.

If the company does not regain compliance by April 5, 2027, it may be eligible for an additional 180-day period if it meets the market value of publicly held shares requirement and all other initial listing standards for The Nasdaq Capital Market except bid price. It would need to give notice that it intends to cure the deficiency, by a reverse stock split if necessary.

The company says it intends to take all reasonable measures to regain compliance within the grace period.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

GDTC

CytoMed Therapeutics Limited

NASDAQ · Singapore

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/cytomed-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-5/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CytoMed Therapeutics gets Nasdaq bid price notice", 2026-10-13, https://aibio.space/news/cytomed-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-5/